Taken together, we demonstrated that miR-153-3p treatment enhanced the chemosensitivity of breast cancer cells to doxorubicin by downregulating KIF20A, leading to disrupted intracellular vesicle formation and doxorubicin-triggered cancer cell death by activating various pathways. The gene discussed is KIF20A; the disease is breast carcinoma.